Access Bio Inc (950130) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.015x

Based on the latest financial reports, Access Bio Inc (950130) has a cash flow conversion efficiency ratio of -0.015x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.16 Billion ≈ $-6.21 Million USD) by net assets (₩599.93 Billion ≈ $406.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Access Bio Inc balance sheet independence to measure how much of total assets are equity-financed.

Access Bio Inc - Cash Flow Conversion Efficiency Trend (2012–2024)

This chart illustrates how Access Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 950130 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Access Bio Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Access Bio Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Arovella Therapeutics Ltd AU:ALA	-0.090x
Astra Exploration Inc V:ASTR	-0.746x
DDC Enterprise Limited NYSE MKT:DDC	-0.021x
Everbrite Technology Co Ltd TWO:4523	-0.042x
Sekuro Plastik Ambalaj Sanayi AS IS:SEKUR	-0.167x
Elinoil Hellenic Petroleum Company S.A AT:ELIN	0.505x
Shagrir Group Vehicle Services Ltd TA:SHGR	0.072x
Northwest Copper Corp V:NWST	-5.572x

Annual Cash Flow Conversion Efficiency for Access Bio Inc (2012–2024)

The table below shows the annual cash flow conversion efficiency of Access Bio Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 950130 market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩442.28 Million ≈ $299.73K	₩13.54 Million ≈ $9.18K	0.031x	+22410.95%
2023-12-31	₩587.14 Billion ≈ $397.90 Million	₩-80.57 Million ≈ $-54.60K	0.000x	-100.02%
2022-12-31	₩487.74 Million ≈ $330.53K	₩291.33 Million ≈ $197.43K	0.597x	+4.71%
2021-12-31	₩241.75 Million ≈ $163.83K	₩137.90 Million ≈ $93.45K	0.570x	-99.88%
2020-12-31	₩76.95 Million ≈ $52.15K	₩36.72 Billion ≈ $24.89 Million	477.222x	+2498.24%
2019-12-31	₩21.22 Million ≈ $14.38K	₩-422.24 Million ≈ $-286.15K	-19.899x	+88.40%
2018-12-31	₩33.42 Million ≈ $22.65K	₩-5.73 Billion ≈ $-3.88 Million	-171.471x	-29.50%
2017-12-31	₩41.13 Million ≈ $27.87K	₩-5.45 Billion ≈ $-3.69 Million	-132.408x	-298039.61%
2016-12-31	₩47.55 Million ≈ $32.22K	₩2.11 Million ≈ $1.43K	0.044x	+19.26%
2015-12-31	₩76.88 Billion ≈ $52.10 Million	₩2.87 Billion ≈ $1.94 Million	0.037x	+197.03%
2014-12-31	₩68.58 Billion ≈ $46.48 Million	₩-2.63 Billion ≈ $-1.79 Million	-0.038x	-221.48%
2013-12-31	₩50.20 Billion ≈ $34.02 Million	₩1.59 Billion ≈ $1.08 Million	0.032x	-62.82%
2012-12-31	₩21.71 Billion ≈ $14.71 Million	₩1.85 Billion ≈ $1.25 Million	0.085x	--

About Access Bio Inc

KQ:950130 Korea Diagnostics & Research

Market Cap

$51.25 Million

₩75.62 Billion KRW

Market Cap Rank

#21720 Global

#1276 in Korea

Share Price

₩2150.00

Change (1 day)

+4.88%

52-Week Range

₩2020.00 - ₩5390.00

All Time High

₩29950.00